Meldex

www.bioprogress.com

Meldex International plc is a specialty pharmaceutical and healthcare business that uses its XGEL polymer technologies to develop and enhance medicines and healthcare products.

It has a portfolio of marketed branded and generic pharmaceutical products and strategic alliances with several global pharmaceutical companies.

The Company is based in Cambridge, Tampa, US and Paris, France.

It is a publicly traded company listed on the Alternative Investment Market of the London Stock Exchange.

It was formerly known as BioProgress plc.

Staff

Steve Martin BSc (Hons) MRPharmS, Commercial Development Director

Steve Martin was appointed Director of Pharmaceuticals of Meldex International in November 2005, with broad experience in commercial development and marketing of pharmaceutical and healthcare products. He was appointed to the Board of Meldex International on 25 July 2006. Prior to this appointment he was the founder and Chief Executive Officer of Vienna Healthcare, a business advising on commercial strategy within the global speciality pharmaceutical markets. Previously he founded and ran the Stevenden Healthcare Group; a UK based speciality pharmaceutical company, owned a small chain of community pharmacies and sat on a number of professional and advisory health committees. He has also developed a number of innovative pharmaceutical products including a number of first-to-market generic products and co-founded a specialist clinical research organisation in the area of topical and transdermal medicines. He is a registered and practising pharmacist and began his career with Paydens, a family-run retail pharmacy and distribution company.
Jean-Francois Sfarti, President Director General and Chief Executive Officer, Dexo SA

Jean-Francoise Sfarti is President Director General and Chief Executive Officer of Dexo and has over 30 years of experience in the pharmaceutical industry. He acquired Dexo eight years ago from its founding family and restructured the company to create a virtual operation by outsourcing manufacturing, marketing and distribution. He has developed its product range through the acquisition of pharmaceuticals and by identifying lucrative marketing and product development/extension opportunities. He started his industry career with Sanofi ultimately becoming its Chief Executive in France. He has a degree in Pharmacy (Paris) and in marketing (Issec, Paris).

Contact details

15 -17 Cambridge Science Park
Milton Road
Cambridge
CB4 0FQ

Tel: +44 (0)1223 394250
Fax: +44 (0)1223 394251
Articles relating to Meldex

Silicon Fen shorts: Meldex signs distribution deal; Cambridge Consultants launch cute Internet radio
Silicon Fen shorts: Cambridge Enterprise Ltd 1st year; GeneMedix relocates to Ireland
SFBR shorts: Changing of the guard at nCipher; Meldex buys antibiotics products for E14.5m
Briefs: Lab21 raises £2.2m; Meldex suspended pending clarity on trading, working capital; Autonomy in big deal with BAE
Tough year on the stock market for Silicon Fen's Top Ten but Autonomy sparkles
Briefs: Meldex CEO leaves “with immediate effect”; Sphere Medical raises £5m
Snippets: Meldex starts EU filing; Recent Uni spin-off CTC raises £0.375m
Silicon Fen shorts: New CEO for EEDA; Meldex 'in play'?
Briefs: CSR’s new Bluetooth software adds 30 minutes to Intel-based PC battery time; Meldex launches new OTC natural alternative to HRT
Meldex sells Dexo for €8.5m in ‘distressed sale’ to repay bankers; well advanced in restructure
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • Biowisdom


Steve Gardner PhD
Chief Technology Officer


BioWisdom Ltd, established in September 2000, builds Intelligence Networks which are used to support decision making in critical issues in all areas of the healthcare industry from early stage drug discovery and clinical development through to market profiling and due diligence on new products. The

[Biowisdom's profile]


Top20 Index




Currently: 161